Bookmark and Share
T6177652 (CID 25162458) - Compound BioActivity Data
.
BioActivity Outcomes:
Active(8)
 
 
Inactive(288)
 
 
Inconclusive(12)
 
 
Unspecified(1)
 
 
Top Targets:
7tm 4(29)
 
 
 
RasGEF(4)
 
 
CAP ED(4)
 
 
Troponin(4)
 
 
ABCC CFTR1(3)
 
 
BioAssay Types:
Screening(218)
 
 
 
 
Confirmatory(79)
 
 
 
 
 
Literature(9)
 
 
BioActivity Types:
Potency(69)
 
 
 
 
 
EC50(5)
 
 
IC50(5)
 
 
Data download

Chemical Probe    Active    Inactive    Inconclusive    Unspecified   

Total Bioassays: 271    Data Row: 309   Total Pages: 16   Display: Page     
Sort: [Click the result table header to sort]
#SubstanceActivityBioAssayTargetLinks
OutcomeTypeValue [μM]
1
[SID57258428]
Potency 12.5893qHTS Assay for Inhibitors of Hepatitis C Virus (HCV) [AID651820, Type: confirmatory]
View
2
[SID57258428]
Potency 23.1093qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT [AID686978, Type: confirmatory]TDP1 protein [Homo sapiens] [gi:79154014]
View
3
[SID57258428]
Potency 23.1093qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT [AID686979, Type: confirmatory]TDP1 protein [Homo sapiens] [gi:79154014]
View
4
[SID57258428]
Luminescence-based cell-based high throughput confirmation assay for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors [AID504904, Type: screening]mu-type opioid receptor isoform MOR-1 [Homo sapiens] [gi:117940060]
View
5
[SID57258428]
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors [AID504326, Type: screening]mu-type opioid receptor isoform MOR-1 [Homo sapiens] [gi:117940060]
View
6
[SID57258428]
HTS to identify compounds that promote myeloid differentiation with MLPCN compound set [AID624256, Type: screening] [geneid:3205]
View
7
[SID57258428]
Luminescence-based cell-based high throughput confirmation assay for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors [AID504904, Type: screening]delta-type opioid receptor [Homo sapiens] [gi:63477962]
View
8
[SID57258428]
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors [AID504326, Type: screening]delta-type opioid receptor [Homo sapiens] [gi:63477962]
View
9
[SID57258428]
Potency qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate [AID624178, Type: confirmatory]acid sphingomyelinase [Homo sapiens] [gi:179095]
View
10
[SID57258428]
Potency 14.1254qHTS for Inhibitors of TGF-b: Cytotox Counterscreen [AID588856, Type: confirmatory]
View
11
[SID57258428]
EC50 22.918Luminescence-based cell-based high throughput dose response assay for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors [AID588407, Type: confirmatory]mu-type opioid receptor isoform MOR-1 [Homo sapiens] [gi:117940060]
View
12
[SID57258428]
EC50 22.918Luminescence-based cell-based high throughput dose response assay for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors [AID588407, Type: confirmatory]delta-type opioid receptor [Homo sapiens] [gi:63477962]
View
13
[SID57258428]
EC50 92.456Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRD1 homodimerization [AID588411, Type: confirmatory]delta-type opioid receptor [Homo sapiens] [gi:63477962]
View
14
[SID57258428]
EC50 92.456Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRM1 homodimerization [AID588435, Type: confirmatory]mu-type opioid receptor isoform MOR-1 [Homo sapiens] [gi:117940060]
View
15
[SID57258428]
EC50 92.456Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based high throughput dose response assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A) [AID588408, Type: confirmatory]5-hydroxytryptamine receptor 5A [Homo sapiens] [gi:13236497]
View
16
[SID57258428]
Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A) [AID504634, Type: screening]5-hydroxytryptamine receptor 5A [Homo sapiens] [gi:13236497]
View
17
[SID57258428]
Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A) [AID504692, Type: screening]5-hydroxytryptamine receptor 5A [Homo sapiens] [gi:13236497]
View
18
[SID57258428]
Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A) [AID504905, Type: screening]5-hydroxytryptamine receptor 5A [Homo sapiens] [gi:13236497]
View
19
[SID57258428]
uHTS identification of small molecule inhibitors of Csn-mediated Deneddylation of Cullin-Ring Ligases, vis a fluorescence polarization assay [AID651999, Type: screening]COP9 signalosome complex subunit 5 [Homo sapiens] [gi:38027923]
View
20
[SID57258428]
MLPCN SirT-5 Measured in Biochemical System Using Imaging - 7044-01_Inhibitor_SinglePoint_HTS_Activity_Set5 [AID652115, Type: screening]NAD-dependent protein deacylase sirtuin-5, mitochondrial [gi:38258652]
View